A possible treatment for MYC+DLBCL is dose-adjusted R-EPOCH [18], however, MYC+ patient numbers are limited and BCL2 status is unknown, hence no conclusions can be drawn. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.